The expression of a nitric oxide derivative, tissue inhibitors of metalloproteinase-3, and tissue inhibitors of metalloproteinase-4 in chronic periodontitis with type 2 diabetes mellitus

Journal of Periodontal and Implant Science

Volumn 43, Issue 2, 2013, Pages 87-95

  Jung, Hyun Yub ^a   Kim, Yong Gun ^a   Park, Jin Woo ^a   Suh, Jo Young ^a   Lee, Jae Mok ^a  

^a Kyungpook National University   (South Korea)

Author keywords

Chronic periodontitis; Diabetes mellitus; Nitric oxide synthase; Tissue inhibitor of metalloproteinases

Indexed keywords

EID: 84880599928     PISSN: 20932278     EISSN: 20932286     Source Type: Journal    
DOI: 10.5051/jpis.2013.43.2.87     Document Type: Article

References (39)

1. Eley B.M., Cox S.W. Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defenses and tissues and detection in gingival crevice fluid. Periodontol 2000 2003;31:105-24.
2. Hou Y.C., Janczuk A., Wang P.G. Current trends in the development of nitric oxide donors. Curr Pharm Des 1999;5: 417-41.
3. Batista A.C., Silva T.A., Chun J.H., Lara VS. Nitric oxide synthesis and severity of human periodontal disease. Oral Dis 2002;8:254-60.
4. Abramson S.B., Amin A.R., Clancy RM, Attur M. The role of nitric oxide in tissue destruction. Best Pract Res Clin Rheumatol 2001;15:831-45.
5. Reher V.G., Zenobio E.G,Costa F.O., Reher P., Soares RV. Nitric oxide levels in saliva increase with severity of chronic periodontitis. J Oral Sci 2007;49:271-6.
6. Kendall H.K., Marshall R.I., Bartold P.M. Nitric oxide and tissue destruction. Oral Dis 2001;7:2-10.
7. Bauer E.A., Stricklin G.P., Jeffrey J.J., Eisen A.Z. Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 1975;64:232-40.
8. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.
9. Young D.A., Phillips B.W., Lundy C., Nuttall R.K., Hogan A., Schultz GA, et al. Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem J 2002;364(Pt 1):89-99.
10. Muhlemann H.R., Son S. Gingival sulcus bleeding: a leading symptom in initial gingivitis. Helv Odontol Acta 1971; 15:107-13.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5-20.
12. Cho J.Y., Xing S., Liu X., Buckwalter T.L., Hwa L., Sferra T.J., et al. Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther 2000;7:740-9.
13. Stefanovic-Racic M., Stadler J., Evans C.H. Nitric oxide and arthritis. Arthritis Rheum 1993;36:1036-44.
14. Allaker R.P., Silva Mendez L.S., Hardie JM, Benjamin N. Antimicrobial effect of acidified nitrite on periodontal bacteria. Oral Microbiol Immunol 2001;16:253-6.
15. Gyurko R., Boustany G., Huang P.L., Kantarci A., Van Dyke T.E., Genco C.A., et al. Mice lacking inducible nitric oxide syn thase demonstrate impaired killing of Porphyromonas gingivalis. Infect Immun 2003;71:4917-24.
16. Ralston S.H., Todd D., Helfrich M., Benjamin N., Grabowski P.S. Human osteoblast-like cells produce nitric oxide and express inducible nitric oxide synthase. Endocrinology 1994;135:330-6.
17. van't Hof R.J., Ralston S.H. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 1997;12:1797-804.
18. Lohinai Z., Benedek P., Feher E., Gyorfi A., Rosivall L., Fazekas A., et al. Protective effects of mercaptoethylguanidine, a selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the rat. Br J Pharmacol 1998;123:353-60.
19. Leitão R.F, Ribeiro R.A., Chaves H.V., Rocha F.A., Lima V., Brito GA. Nitric oxide synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005;76:956-63.
20. Lin S.K., Kok S.H., Kuo M.Y., Lee M.S., Wang C.C., Lan W.H., et al. Nitric oxide promotes infectious bone resorption by enhancing cytokine-stimulated interstitial collagenase synthesis in osteoblasts. J Bone Miner Res 2003;18:39-46.
21. Alayan J., Ivanovski S., Gemmell E., Ford P., Hamlet S., Farah C.S. Deficiency of iNOS contributes to Porphyromonas gingivalis-induced tissue damage. Oral Microbiol Immunol 2006;21:360-5.
22. Takahashi Y., Nakano T., Wakabayashi I. Increased induction of inducible nitric oxide synthase expression in aortae of type 2 diabetes rats. J Pharmacol Sci 2008;107:190-200.
23. Pereira F.O., Frode T.S., Medeiros Y.S. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm 2006;2006: 39062.
24. Nagareddy P.R., McNeill J.H., MacLeod K.M. Chronic inhibition of inducible nitric oxide synthase ameliorates cardiovascular abnormalities in streptozotocin diabetic rats. Eur J Pharmacol 2009;611:53-9.
25. Kashyap S.R., Roman L.J., Lamont J., Masters B.S., Bajaj M., Suraamornkul S., et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 2005; 90:1100-5.
26. Lappin D.F., Kjeldsen M., Sander L., Kinane D.F. Inducible nitric oxide synthase expression in periodontitis. J Periodontal Res 2000;35:369-73.
27. Nishikawa T., Naruse K., Kobayashi Y., Miyajima S., Mizutani M., Kikuchi T., et al. Involvement of nitrosative stress in experimental periodontitis in diabetic rats. J Clin Periodontol 2012;39:342-9.
28. Garlet G.P., Cardoso C.R., Campanelli A.P., Ferreira B.R., Avila-Campos M.J., Cunha F.Q., et al. The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: host protection and tissue destruction. Clin Exp Immunol 2007;147:128-38.
29. Garlet G.P., Martins W.Jr, Fonseca B.A., Ferreira B.R., Silva J.S. Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. J Clin Periodontol 2004;31:671-9.
30. Kubota T., Itagaki M.. Hoshino C., Nagata M., Morozumi T., Kobayashi T., et al. Altered gene expression levels of matrix metalloproteinases and their inhibitors in periodontitis-affected gingival tissue. J Periodontol 2008;79:166-73.
31. Nakasone N., Kubota T., Hoshino C., Nohno K., Itagaki M., Shimizu T., et al. Differential gene and protein expression of tissue inhibitors of metalloproteinases (TIMP)-3 and TIMP-4 in gingival tissues from drug induced gingival overgrowth. Arch Oral Biol 2009;54:634-41.
32. Claudino M., Trombone A.P., Cardoso C.R., Ferreira S.B. Jr, Martins W.Jr, Assis G.F., et al. The broad effects of the functional IL-10 promoter-592 polymorphism: modulation of IL-10, TIMP-3, and OPG expression and their association with periodontal disease outcome. J Leukoc Biol 2008;84: 1565-73.
33. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
34. Garlet G.P., Cardoso C.R., Silva T.A., Ferreira B.R., Avila-Campos M.J., Cunha F.Q., et al. Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. Oral Microbiol Immunol 2006;21:12-20.
35. Cochran D.L. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79(8 Suppl):1569-76.
36. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998;435:39-44.
37. Monroy A., Kamath S., Chavez A.O., Centonze V.E., Veerasamy M., Barrentine A., et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 2009;52:2169-81.
38. Cardellini M., Menghini R., Martelli E., Casagrande V., Marino A., Rizza S., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009;58:2396-401.
39. Koskivirta I., Rahkonen O., Mayranpaa M., Pakkanen S., Husheem M., Sainio A., et al. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 2006;126:335-42.